三阴性乳腺癌靶向治疗研究进展

三阴性乳腺癌（TNBC）作为乳腺癌一种预后较差的亚型，在出现化疗药物抵抗的情况下，由于缺少其他有效治疗方法，疾病往往易快速复发转移。因此针对TNBC新治疗靶点及靶向药物的研究已成为目前国内外研究热点。本文主要针对目前TNBC靶向治疗研究进展进行总结分析，主要包括ADP合同聚合酶抑制剂、抗血管生成靶向药物、抗表皮生长因子受体信号通路靶向药物、雄激素受体拮抗剂、免疫检查点抑制剂、PI3K-AKT-mTOR通路抑制剂等，以期从中找出最有可能成为未来发展方向的靶向治疗方法。

Research progress on targeted therapy of triple negative breast cancer

As a subtype of breast cancer, triple negative breast cancer (TNBC) is characterized by poor prognosis. In thecase of chemotherapeutic drug resistance, local recurrence and distant metastasis always occur rapidly due to lack of other effective treatments. Therefore, clinical research on new therapeutic target and targeted therapy of TNBC has become a hot spot. This paper focused on the current research progress of TNBC targeted therapy, including PARP inhibitors, antiangiogenesis, anti-epidermal growth factor receptor, androgen receptor antagonists, immune checkpoint inhibitors and PI3KAKT-mTOR inhibitors, in order to find out the most likely to be the direction of targeted therapy for future development.